Verification evidence is still being completed.
PDF / print export
Adcendo ApS
Copenhagen, Denmark
- Verified lead
- Michael Pehl
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Antibody-Drug Conjugates, uPARAP-Targeted Oncology, and Soft-Tissue Sarcoma Clinical Development
- Review cycle
- 24 April 2026
- Full address
- BioInnovation Institute, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Adcendo Series C 2025 financing release confirming Michael Pehl as Chief Executive Officer.
- Editorial note
- Copenhagen BioInnovation Institute-based ADC biotech with named CEO, 75 million USD 2025 Series C, FDA Fast Track for ADCE-D01, and dual-site Copenhagen plus Boston operations.
Antibody-Drug Conjugates, uPARAP-Targeted Oncology, and Soft-Tissue Sarcoma Clinical Development
FDA Fast Track designation, Public CEO disclosure via Series C release, BioInnovation Institute tenancy
Copenhagen BioInnovation Institute-based ADC biotech with named CEO, 75 million USD 2025 Series C, FDA Fast Track for ADCE-D01, and dual-site Copenhagen plus Boston operations.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Copenhagen, Denmark
Adcendo ApS
Antibody-Drug Conjugates, uPARAP-Targeted Oncology, and Soft-Tissue Sarcoma Clinical Development · Clinical-stage ADC development
Copenhagen BioInnovation Institute-based ADC biotech with named CEO, 75 million USD 2025 Series C, FDA Fast Track for ADCE-D01, and dual-site Copenhagen plus Boston operations.
- Lead
- Michael Pehl (verified ↗)
- Address
- BioInnovation Institute, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark (source ↗)
- Compliance
- FDA Fast Track designation
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage ADC development
- Capabilities
- ADC Discovery and Development · Clinical-Stage Sarcoma Program · Copenhagen and Boston Operations
- Founded
- 2017
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Michael Pehl
Chief Executive Officer
Full addressBioInnovation Institute, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
ADC Directory member listing for Adcendo at Ole Maaloes Vej 3, Copenhagen.
Open sourceClinical-stage ADC development
Copenhagen, Denmark. Antibody-Drug Conjugates, uPARAP-Targeted Oncology, and Soft-Tissue Sarcoma Clinical Development. Review completed on 24 Apr 2026.
Danish Medicines Agency, EMA, and FDA for clinical oversight
FDA Fast Track designation, Public CEO disclosure via Series C release, BioInnovation Institute tenancy
Antibody-Drug Conjugates, uPARAP-Targeted Oncology, and Soft-Tissue Sarcoma Clinical Development
Copenhagen BioInnovation Institute-based ADC biotech with named CEO, 75 million USD 2025 Series C, FDA Fast Track for ADCE-D01, and dual-site Copenhagen plus Boston operations.
Editorial note
Adcendo anchors Danish ADC development from the BioInnovation Institute with a named CEO, a 75 million USD 2025 Series C, an FDA Fast Track-designated lead program in sarcoma, and documented Copenhagen plus Boston operations.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
ADC Discovery and Development
Clinical-Stage Sarcoma Program
Copenhagen and Boston Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
ADC discovery platform
Clinical trial operations
Partner CDMO supply chain
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Adcendo ApS located?
- Adcendo ApS operates from BioInnovation Institute, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark, Copenhagen, Denmark.
- Who runs Adcendo ApS?
- Adcendo ApS is led by Michael Pehl, Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does Adcendo ApS hold?
- Adcendo ApS is documented under FDA Fast Track designation.
- What does Adcendo ApS do?
- Copenhagen BioInnovation Institute-based ADC biotech with named CEO, 75 million USD 2025 Series C, FDA Fast Track for ADCE-D01, and dual-site Copenhagen plus Boston operations. Core capabilities: ADC Discovery and Development, Clinical-Stage Sarcoma Program, Copenhagen and Boston Operations.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.